Lung allograft injury improves after gastroesophageal reflux surgery by donor-derived cell-free DNA kinetics

= 0.0625), respectively. All patients experienced clinical improvement (assessed by spirometry or resolution of recurrent aspiration pneumonia events). These data suggest that dd-cfDNA may have expanded utility as a non-invasive clinical tool to identify molecular injury sequelae of gastroesophageal reflux. Given the limited effective treatment options for CLAD, we envision an opportunity for the use of dd-cfDNA to reduce the risk of CLAD development when GERD is involved.